Tirzepatide

Tirzepatide

Learn about

Tirzepatide

Tirzepatide is a dual GLP-1/GIP receptor agonist medication approved for medically supervised weight loss and blood sugar management. It targets two separate hormone pathways involved in appetite regulation and metabolism, often producing greater weight loss than single-pathway medications. Tirzepatide works by mimicking two incretin hormones that regulate appetite, insulin sensitivity, and food intake.

Dual-Action Weight Loss, Medically Supervised.

At Elite Medical Solutions, Tirzepatide treatment is managed by Sarina Howard, PA-C. Clinical trials show patients can achieve average weight loss exceeding 20% of total body weight over 72 weeks when combined with lifestyle changes.

Superior Clinical Results:

Clinical trials show Tirzepatide can produce average weight loss exceeding 20% of total body weight over 72 weeks — among the highest results of any weight loss medication studied.

Dual Hormone Pathway:

Tirzepatide activates both GLP-1 and GIP receptors, offering appetite suppression and metabolic benefits beyond what single-pathway medications provide.

Weekly Injection:

Like Semaglutide, Tirzepatide is administered as a once-weekly injection, fitting easily into your routine.

Medical Supervision:

Your treatment is monitored by Sarina Howard, PA-C, with regular check-ins to adjust dosing and track progress safely.

Blood Sugar Benefits:

Tirzepatide was originally developed for type 2 diabetes management and offers meaningful improvements in blood sugar control alongside weight loss.

Gradual Dose Titration:

Treatment begins at a low dose and increases gradually under medical guidance to minimize side effects while optimizing results.

Frequently Asked Questions

Clinical trials show average weight loss exceeding 20% of total body weight over 72 weeks when combined with diet and exercise, though individual results vary.

Tirzepatide activates both GLP-1 and GIP receptors, while Semaglutide activates only GLP-1. This dual mechanism often produces greater average weight loss for Tirzepatide patients.

Candidates typically have a BMI of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher. A consultation with Sarina Howard PA-C will confirm eligibility.

The most common side effects are nausea, diarrhea, and decreased appetite, particularly during dose escalation. These generally improve with time and are monitored by your provider.

Schedule A Consultation

Contact us to schedule a consultation and find out more about this procedure.

Featured Navigation

Semaglutide
Tirzepatide